Open access peer-reviewed Edited Volume

Acute Leukemias

Pier Paolo Piccaluga

University of Bologna


Acute Myeloid Leukemia Leukemic Stem Cell Chemotherapy Anthracyclines Personalized Medicine CAR-T cell Next-generation Sequencing Cytogenetics Cytarabine Stem Cell Transplantation Targeted Treatment CNS Prophylaxis

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Acute myeloid leukemia (AML) is the common set acute leukemia in adults, while acute lymphoid leukemia (ALL) is the commonest cancer in childhood. For many years, the diagnosis of "leukemia" has represented a death penalty for our patients. However, in the last decades, tremendous progress has been made, leading to establishing ALL as one of the most curable malignancies (at least as far as the pediatric setting is concerned), to overall save around 50% of adult patients, and to cure without chemotherapy one of the most aggressive AML subtypes, the acute promyelocytic leukemia. Major advances have regarded both biology and, consequently, the treatment of these diseases. Particularly, the discovery of the genetic basis for many leukemia subtypes led to improve our prognostic capability, the possibility to modulate toxicity based on the risk, and eventually novel targeted approaches (eg. tyrosine kinase inhibitors for BCR/ABL1-positive ALL and anti-FLT3 for a subset of AML). Finally, patients' management has significantly benefitted from the improvements in cellular therapies, including stem cell transplantation and, more recently, the adoption of CAR-T cells, especially for ALL.

This book intends to provide the reader with a comprehensive overview of the current state-of-the-art in acute leukemias pathobiology, classification, and treatment, with special emphasis on the most important evidence-based developments.

Publishing process

Book initiated and editor appointed

Date completed: May 28th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: August 17th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: November 5th 2020

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: January 4th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Pier Paolo Piccaluga

University of Bologna

Dr. Piccaluga is an Associate Professor of Pathology, at the Department of Experimental, Diagnostic and Specialty Medicine at the Bologna University School of Medicine, Genomics and Personalized Medicine laboratory (September 2012-present). He started working as an Adjunct Professor at the Jomo Kenyatta University of Agricolture and Technology (Nairobi, Kenya) and Temporary Professor at Queen Mary University of London (UK) in 2018. and he works in programs in Hematopathology and Molecular Diagnostics, IEMEST, Palermo (2016-present). In 1997. he received his Degree in Medicine and Surgery with honors. In 2001. he finished his Specialty in Hematology with honors and in 2005. a PhD in Clinical and Experimental Hematology. From 2003. to 2004. he served as a Post doctoral research fellow at the Institute for Cancer Genetics (Columbia University, New York, NY). In 2008. he was a Visiting Scientist at the Center for Computational Biology and Bioinformatics, Columbia University Medical Center. The same year he was a Core Lab Director – Core Lab Program Affymetrix, Oncopharmagen Group In 2009. he worked as a Visiting Scientist at the Institut fur Pathologie, Christian-Albrechts-University, Kiel, Germany. From 2006 to Assistant Professor in Pathology, Unit of Hematopathology, Department of Hematology and Oncological Sciences \L. & A. Seràgnoli\, University of Bologna; Responsible for Molecular Pathology Laboratory. In he 2014. he obtainment the 'Abilitazione Nazionale a Professore Ordinario*, SSD MED/08” (*Full Professorship). In 2014- he also completed his Specialty in Pathology with honors at the University of Siena He is the author of several international publications with total impact factor >1,000; mean impact factor >6, H-index: 56. He has Three patents on molecular diagnostic tools for hematological cancers. He is involved in several clinical trials as coordinator or sub-investigator. Winner of several prizes for study and research. Dr. Piccaluga is Involved/PI in several research project granted by national and international recognized organisms and he is also an Associate Editor for numerous journals.

View profile

Book chapters authored 4

Books edited 1

Introducing your Author Service Manager

Ms. Dajana Pemac

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in